Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 13Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Glioblastoma 4Colorectal Neoplasms 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Disease 3Carcinoma, Hepatocellular 3Carcinoma 3Ureteral Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anatomic Stage II Breast Cancer AJCC v8 × Magnetic Resonance Spectroscopy × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡